Dr. Lindner graduated from the Des Moines University College of Osteopathic Medicine in 1989. He works in Naples, FL and specializes in Pulmonary Disease and Pulmonary Critical Care Medicine. Dr. Lindner is affiliated with NCH Downtown Naples Hospital and NCH North Naples Hospital.
Name / Title
Company / Classification
Phones & Addresses
David J. Lindner
1901 FOOD SERVICES, LLC
David J. Lindner
GAVI'S RIVER, LLC
David J Lindner
695 CLUB DRIVE, LLC
David J. Lindner
PARKLAND INVESTMENTS, LLC
David J. Lindner
ANNA DEAN CONDOMINIUM ASSOCIATION, INC
David J. Lindner
FAIRWAYS AT BOULDER CREEK UNIT OWNERS ASSOCIATION, INC
Strategic Relationship Executive & Client Partner at Fiserv
Location:
Flower Mound, Texas
Industry:
Financial Services
Work:
Fiserv since Feb 2011
Strategic Relationship Executive & Client Partner
Fiserv May 2006 - Feb 2011
Business & Product Development Director
Intervoice Jul 2005 - May 2006
Director, Enterprise Hosted Solutions
Intervoice Jun 2004 - Jul 2005
Director, Product & Market Management
Intervoice Oct 2000 - Jun 2004
Strategic Account Director
Education:
Southern Methodist University - Cox School of Business 1999 - 2001
Vanderbilt University - Owen Graduate School of Management 1998 - 1999
University of Southern Mississippi 1981 - 1985
Katherine E. Brighty - Groton CT David L. Lindner - Niantic CT
Assignee:
Pfizer Inc. - New York NY
International Classification:
C07D49904 A61K 31425
US Classification:
540214
Abstract:
An efficient process for converting readily available 4-acetoxy-2-azetidinones to allyl 2-thioxopenam-3-carboxylates, intermediates useful for the synthesis of penem antibiotics.
Intermediates For 2-(1-Oxo-3-Thiolanyl)-2-Penem Antibiotics
Robert A. Volkmann - Ledyard CT David L. Lindner - Niantic CT
Assignee:
Pfizer Inc. - New York NY
International Classification:
C07D49900 A61K 31425
US Classification:
540310
Abstract:
Process and intermediates for the conversion of 3R,4R-4-acetoxy-3-[1R-1-(silyloxy)ethyl]-2-azetidinones to antibacterial 5R,6S-6-(1R-1-hydroxyethyl)-2-(1-oxo-3-thiolanylthio)-2-penem-3-carboxylic acids, and the pharmaceutically-acceptable salts and pivaloyloxymethyl esters thereof.
Process For 2-(1-Oxo-3-Thiolanyl)-2-Penem Antibiotics
Robert A. Volkmann - Ledyard CT David L. Lindner - Niantic CT
Assignee:
Pfizer Inc. - New York NY
International Classification:
C07D49900 A61K 31545
US Classification:
540310
Abstract:
Process and intermediates for the conversion of 3R,4R-4-acetoxy-3-[1R-1-(silyloxy)ethyl]-2-acetidinones to antibacterial 5R,6S-6-(1R-1-hydroxyethyl)-2-(1-oxo-3-thiolanylthio)-2-penem-3-carboxylic acids, and the pharmaceutically-acceptable salts and pivaloyloxymethyl esters thereof.
Robert A. Volkmann - Ledyard CT David L. Lindner - Niantic CT
Assignee:
Pfizer Inc. - New York NY
International Classification:
C02D40912
US Classification:
540354
Abstract:
Process and intermediates for the conversion of 3R,4R-4-acetoxy-3-[1R-1-(silyloxy)ethyl]-2-azetidinones to antibacterial 5R,6S-6-(1R-1-hydroxyethyl)-2-(1-oxo-3-thiolanylthio)-2-penem-3-carboxylic acids, and the pharmaceutically-acceptable salts and pivaloyloxymethyl esters thereof.
News
SWFL doctors, residents reacting to omicron COVID-19 variant
This is going to become the dominant variant in all likelihood worldwide, and should be considered a very high-risk variant, said Dr. David Lindner, the COVID-19 response leader for NCH. I think the key points are that this variant went from a few sequence cases, to the dominant variant in days o
Date: Nov 29, 2021
Category: More news
Source: Google
SWFL health systems set to receive new monoclonal antibody treatment
They have synthesized monoclonal antibodies to mimic that same response, and now its in an infusion that we can give that basically will then target COVID-19, said Dr. David Lindner, who leads the NCH Health Systems COVID-19 response team.